Podcasts about Novo Nordisk

Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.Background reading: How Ozempic's maker lost its shine after creating a wonder drug.What Trump's new drug pricing deal means for people with obesity.Photo: Sergei Gapon/Agence France-Presse — Getty ImagesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

From the research facilities of Novo Nordisk, Copenhagen-born, Lexington, Massachusetts-based Danish scientist and senior vice president JACOB STEN PETERSEN talks about his 35-year career working in developing drugs to support patients with serious chronic diseases, and his 25-year long work and personal investment in finding a cure for diabetes. Jacob further shares his thoughts on the cultures between Denmark and the US regarding the pharmaceutical industry and healthcare system.Jacob selects a work by Per Kirkeby from the SMK collection.https://open.smk.dk/en/artwork/image/KMS8278(Photographer: Greg M. Cooper)----------We invite you to subscribe to Danish Originals for weekly episodes. You can also find us at:website: https://danishoriginals.com/email: info@danishoriginals.com----------And we invite you to donate to the American Friends of Statens Museum for Kunst and become a patron: https://donorbox.org/american-friends-of-statens-museum-for-kunst

Pharma juggernauts Pfizer and Novo Nordisk are struggling in the obesity drug race.The two companies are searching for their next moneymaker, and that search recently spun out into a ferocious, multibillion-dollar battle for control of biotech start-up Metsera. The FT's US deals and activism correspondent Oliver Barnes walks through the tussle that's involved lawsuits, public barbs and political drama. Clips from CNBC, Pfizer, Yahoo Finance- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading and listening:Weight-loss wars: $10bn hostile battle pits Pfizer against Novo NordiskPfizer shows hardball mettle needed to win in 2025 M&AThere is only one winner in the Pfizer Novo Nordisk showdownOzempic's unconventional origins- - - - - - - - - - - - - - - - - - - - - - - - - - Attend the FT Global Banking Summit, 2-4 December in London: Enter SAVE20 for a 20% discount, register here.- - - - - - - - - - - - - - - - - - - - - - - - - - Follow Oliver Barnes on X (@mroliverbarnes), or on Bluesky (@mroliverbarnes.bsky.social) Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. Hosted on Acast. See acast.com/privacy for more information.

Timestamps:6:03 – Breakdown of FICO15:15 – Futures Trading Tip of the Week18:37 – Trump's $2K Tariff Plan34:46 – Burry's Shorts on NVDA & Palantir46:00 – What to Do After Becoming a Millionaire59:00 – Is Google the Sleeper AI Giant?1:04:10 – Holiday Market Play: Crypto or Stocks?1:08:20 – Trump x NVO x LLY Partnership Breakdown1:15:46 – Pre-Recession Indicators to Watch1:24:53 – CMG vs. CAVA Investment Outlook1:28:20 – End of Government Shutdown1:32:00 – Key Market Indicators for 20271:33:22 – Weekly Earnings RecapIn this week's Market Mondays, we break down everything from Trump's $2,000 plan to the future of AI and the latest market indicators signaling what's ahead for investors.We start with a deep dive into FICO scores and how they impact your financial future, then move into futures trading tips and Trump's bold plan to give every American $2,000 from tariff profits.We also discuss Michael Burry's short positions against Nvidia and Palantir, whether Google is the sleeper giant in AI, and what to do after you become a millionaire.Plus — we analyze Trump's new partnership with Novo Nordisk and Eli Lilly, what it means for biotech investors, and which markets — crypto or stocks — to focus on during the holiday season.As the government shutdown ends, we reveal key pre-recession indicators to watch, whether Chipotle (CMG) or CAVA are smart plays right now, and what signals could define the path to 2027.#MarketMondays #EarnYourLeisure #Investing #StockMarket #Crypto #FuturesTrading #TrumpEconomy #AIStocks #NVDA #Google #Palantir #NVO #LLY #FinancialEducation #WealthBuilding #RecessionPrep #EYLOur Sponsors:* Check out PNC Bank: https://www.pnc.com* Check out Square: https://square.com/go/eylSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

With ObesityWeek yielding eye-catching amylin data and a bidding war that ran to $10 billion for Metsera, weight loss companies were center stage in biotech last week. On the latest edition of the BioCentury This Week podcast, BioCentury's analysts explained why Pfizer's victory for the start-up over European rival Novo Nordisk doesn't necessarily mean a broader U.S. policy shift against foreign acquisitions of domestic biotechs.Turning to ObesityWeek readouts, they discuss Eli Lilly's data for amylin monotherapy eloralintide, arguing that just as Lilly did with GLP-1 agonists, the company is again setting the benchmark by which all other molecules in the class will be measured.BioCentury's analysts also discuss takeaways from Washington Editor Steve Usdin's Commentary, which finds FDA in a crisis of politicized decisions, plummeting morale, and a hollowed workforce, and highlights from BioCentury's interview with gene therapy pioneer Jim Wilson as he rethinks the funding model for ultrarare disease therapies to keep his mission on track. This episode of the BioCentury This Week podcast is brought to you by Voyager Therapeutics.View full story: https://www.biocentury.com/article/657545#ObesityWeek #Amylin #GLP1 #Eloralintide #DrugMechanism #FDA #RareDisease #GeneTherapy00:01 - Sponsor Message: Voyager Therapeutics 01:53 - Pfizer Wins Metsera08:48 - Lilly's Amylin Data13:06 - Funding Ultrarare Therapies20:51 - What's Next for FDATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

The federal government shutdown is still dragging on — now stretching into its second month — freezing key economic data and labor reports. This adds more uncertainty to already shaky markets, which are struggling under tariffs. Meanwhile, major developments are unfolding in the courts, from a pivotal Supreme Court case that could redefine presidential power over tariffs to an antitrust battle involving Pfizer and Novo Nordisk.At the state level, voters weighed in on key tax and spending measures that will shape local economies for years to come. A lot is happening across every level of government — and each of these stories ties back to one question: how do we keep America's economy free, competitive, and growing? In This Week's Economy, I explore this question in light of recent news. You can catch the full episode on YouTube, Apple Podcast, or Spotify.Visit: VanceGinn.comSubscribe: VanceGinn.Substack.com

S&P futures are pointing higher today. Asia equities ended higher, Europe opened with strong gains. US dollar unchanged. Treasury yields higher across tenors, JGB yields also up. Crude oil futures higher. Precious metals up with gold back above $4K. Base metals mixed. Cryptocurrencies also rallying. Risk sentiment supported on news that US Senate is nearing deal to end government shutdown with enough Democrats in support. Compromise said to involve fully funding Departments of Agriculture and Veterans Affairs for a year while partially funding other agencies through 30-Jan. Agreement guarantees laid-off federal employees will be re-hired and given backpay. Any deal would also unblock release of delayed economic data, providing colour on December rate cut prospects. White House also warned of a potentially negative Q4 GDP print from shutdown that extended past Thanksgiving. Companies Mentioned: Accor, Metsera, Pfizer, Novo Nordisk

In this powerful episode, I will break down one of the biggest developments in obesity and diabetes treatment in U.S. history. Two major pharmaceutical companies - Eli Lilly and Novo Nordisk - have reached a groundbreaking agreement with the administration that will drastically reduce the prices of popular medications like Wegovy, Ozempic, and Zepbound. This pricing model could transform how obesity medications are covered, distributed, and accessed across Medicare, Medicaid, and direct-to-consumer platforms. Tune in to learn what this new deal means for patients, healthcare providers, and public health overall—and why it's being called a game changer for people struggling with obesity and related health conditions. Episode Highlights: Major price cuts announced for Wegovy, Ozempic, and Zepbound under a new federal deal   Medicare to cover obesity drugs for the first time through a five-year pilot program   Medicaid given the option to join discounted pricing starting 2026   Team Rx launches a direct-to-consumer model cutting out costly middlemen   Lower cash prices for GLP-1 medications and upcoming oral versions   Eli Lilly and Novo Nordisk to invest billions in U.S. manufacturing   Program expected to improve access, affordability, and supply of obesity and diabetes meds   Ongoing push for the Treat and Reduce Obesity Act to expand national coverage   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

The U.S. Senate progressed a deal towards ending the longest U.S. Government shutdown in history. Eight democrats joined all but one republican in voting to move forward with a funding bill that will keep the U.S. Government liquid through January 30th, drawing rebuke from Democratic party leaders given the deal's lack of guarantees on healthcare. Meanwhile, China will resume exports of Nexperia chips following a row with the Dutch government, potentially giving a boost to the autos industry which had been hit by the supply shock. In pharma news, the battle between Pfizer and Novo Nordisk for weight-loss biotech Metsera has ended, with the Danish conglomerate losing out in the $10 billion deal.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über wacklige KI-Börsen, den neuen Plan für Siemens Healthineers und was diese Woche sonst noch wichtig wird. Außerdem geht es um Palantir, Nvidia, Meta, Microsoft, ASML, SAP, Infineon, Volkswagen, Siemens, Altair, Rumble, Northern Data, Merck & Co., Amgen, Regeneron Pharmaceuticals, Sanofi, AstraZeneca, Novo Nordisk, Eli Lilly, Robinhood und Walmart. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this week's episode of Dividend Talk we kick off with Kimberly-Clark's surprise move to buy Kenvue, asking if it's a smart acquisition or a future balance-sheet headache. Then we review Q3 earnings from Novo Nordisk, Wolters Kluwer, and Ahold Delhaize, three European dividend powerhouses facing very different challenges.Novo Nordisk's obesity drugs, valuation reset, and dividend safety dominate the discussion, while Wolters Kluwer's high-PE sell-off and the impact of AI on research businesses spark debate on fair value and buybacks. We also look at Snap-on's double-digit dividend hike and Simon Property Group's steady income growth for REIT investors.Later, we revisit our “Monthly Dividend Portfolio” challenge from 2022, checking how picks like Altria, AbbVie, Johnson & Johnson, Realty Income, Shell, and Texas Instruments performed with lessons on dividend growth, yield, and diversification.In the listener Q&A, we cover:Dividend tax strategies and EU exit taxes How to handle rising wealth taxes as a dividend investor Fair-value analysis vs Morningstar valuations Our take on Volkswagen, General Mills, GreenCoat UK, ExxonMobil vs Chevron, and the global renewable-energy transition Thoughts on Unilever's upcoming Magnum spinoff SEE YOU ON THE INSIDE!!Tickers discussed: KMB, KVUE, NVO, LLY, PFE, WKL.AS, AD.AS, SNAP-ON, SPG, MO, ABBV, JNJ, O, TXN, SHEL, GIS, XOM, CVX, UKW.LJoin us:[Facebook] – Https://www.facebook.com/groups/dividendtalk⁠[Twitter] – @DividendTalk_ , @European_DG[Discord] – ⁠https://discord.gg/nJyt9KWAB5⁠[Premium Services] – ⁠https://dividendtalk.eu/download-your-free-samples/⁠[Malmo Meetup] – ⁠https://t.co/STgV1nMWKj

Mamdani se convierte en el primer alcalde musulmán de Nueva York.La demócrata, Mikie Sherrill conquista la gobernación de NJ.Caminar más podría ayudar a retrasar el Alzheimer.ICE detiene a educadora en una guardería hispana de Chicago.Presidente Trump acuerda mejores precios con Eli Lili y Novo Nordisk.Aranceles ante la Corte Suprema.Hayan muerto a un padre, antes del juicio por la muerte de su hija.Ponte al día con lo mejor de ‘La Edición Digital del Noticiero Univision' con Carolina Sarassa y Borja Voces.

In Part 1 we looked at an early study of GLP1 drugs and muscle loss. Today we'll look at two more recent studies, one for Eli Lilly's drug tirzepatide and one for Novo Nordisk's drug semaglutide. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Welcome to Ozempic Weightloss Unlocked, the podcast where we break down the latest developments in semaglutide medications and what they mean for your health. I'm your host, and today we're diving into the most important updates from 2025.Let's start with what's working. Ozempic continues to demonstrate significant effectiveness for weight loss, producing mean weight reduction of fourteen point nine to seventeen point four percent over sixty eight weeks in people without diabetes. The higher dose formulation, known as Wegovy, shows even more impressive results, with studies consistently showing greater average weight loss compared to the lower doses found in Ozempic. For millions managing type two diabetes or seeking weight management solutions, these medications have become game changers.But here's what listeners need to know right now. Recent research is raising important safety concerns that demand our attention. A June 2025 study published in JAMA Ophthalmology found that patients taking semaglutide were twice as likely to develop neovascular age related macular degeneration, a condition that gradually destroys central vision. While the absolute risk remains small, researchers from the University of Toronto identified this link as statistically significant. The mechanism makes sense too. Semaglutide alters vascular and inflammatory pathways directly implicated in macular degeneration.The vision concerns aren't the only ones. A January 2025 study in JAMA Otolaryngology found that patients initiating Glucagon like Peptide One receptor agonist therapy had a significantly increased risk of thyroid cancer diagnosis within the first year of use compared to other diabetes medications. Researchers analyzed data from over three hundred fifty thousand adults with type two diabetes.Then there's gastroparesis, the stomach paralysis condition that's become central to ongoing litigation. Multiple lawsuits allege that Novo Nordisk, the manufacturer, failed to provide adequate warnings about this risk. The lawsuits argue the company knew or should have known about the potential link based on clinical studies and medical literature. Patients reported persistent vomiting, nausea, and extreme stomach discomfort after starting the medication.The legal landscape shifted in December 2024 when the Judicial Panel on Multidistrict Litigation ruled to expand the Glucagon like Peptide One receptor agonist lawsuit to include claims involving Saxenda, though blood clot related injuries were excluded due to complexity concerns.What does this mean for you? If you're considering Ozempic or Wegovy, talk to your doctor about these emerging risks alongside the proven benefits. If you're already taking these medications and experiencing vision changes, thyroid issues, or stomach problems, document everything and consult your healthcare provider.The story of Ozempic isn't finished. As evidence emerges, companies face questions not just about what they disclosed but about what they should have investigated. The scientific community continues watching as more data arrives.Thank you so much for tuning in to Ozempic Weightloss Unlocked. Please subscribe to stay updated on the latest developments in semaglutide research and safety updates. This has been a Quiet Please production. For more, check out Quiet Please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Three more suspects, including two affluent New Jersey teens, are now charged in a foiled ISIS-inspired Halloween terror plot, bringing the total to five. The FAA is cutting up to 10% of flights at 40 major airports as the government shutdown enters week six, triggering nationwide delays. President Trump announces a deal with Eli Lilly and Novo Nordisk to slash the cost of popular GLP-1 weight-loss drugs like Wegovy and Ozempic to about $350 through a new program called TrumpRX. Former House Speaker Nancy Pelosi, 85, announces she will not seek reelection after nearly four decades in Congress and two impeachments of President Trump. Geviti: Go to https://gogeviti.com/megynand get 20% off with code MEGYN. Walmart: Learn how Walmart is fueling the future of U.S. manufacturing at https://Walmart.com/America-at-work Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today's Headlines: House Democrats want no-longer-Prince Andrew to testify about his ties to Jeffrey Epstein. Meanwhile, Nancy Pelosi announced her retirement, with California Sen. Scott Wiener emerging as the establishment pick — though AOC's ex–campaign manager Saikat Chakrabarti plans to run too. A federal judge ruled again that Trump must fully fund SNAP benefits by today, but the DOJ is appealing. Trump also struck a deal with Eli Lilly and Novo Nordisk to cap Ozempic-style drugs at $50 for Medicare and Medicaid patients next year. In smaller but iconic justice news, the D.C. “sandwich guy” who threw a sub at an ICE agent was found not guilty of assault. The Heritage Foundation is in “open revolt” after its president defended Tucker Carlson for hosting white supremacist Nick Fuentes. Staffers, including members of its antisemitism task force, have quit. Meanwhile, FIFA announced a mysterious new “peace prize” ahead of the World Cup draw in D.C., which insiders say Trump demanded after missing out on a Nobel. And Tesla's board is set to hand Elon Musk a $1 trillion compensation deal. Resources/Articles mentioned in this episode: Politico: House Oversight Democrats call on embattled royal Andrew Windsor to testify - Live Updates Politico: California's attorney general endorses Scott Wiener to succeed Pelosi NYT: Judge Orders Trump Administration to Fully Fund SNAP Benefits This Month WaPo: Trump, long fixated on ‘fat drug,' announces deal to lower its price WaPo: Jury finds D.C. ‘sandwich guy' not guilty of assaulting officer WaPo: Heritage staff in open revolt over leader's defense of Tucker Carlson Axios: Trump teased as possible first FIFA Peace Prize winner CNBC: Elon Musk expected to prevail in Tesla shareholder vote over CEO's $1 trillion pay plan  Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

¡Emprendeduros! En este episodio Rodrigo nos da una actualización de mercado donde habla del estatus del mercado, del mercado de empleo y de la manufactura en el pais. Nos da los reportes de ingresos de Palantir, Uber, Shopify, AMD, Novo Nordisk, McDonald's y AppLovin. Después habla de la compra de Kenvue por Kimberly Clark y de la semana ocupada de Elon Musk. Finalmente contestara unas preguntas de los Emprendeduros. ¡Síguenos en Instagram! Rodrigo: https://www.instagram.com/rodnavarro Emprendeduros: https://www.instagram.com/losemprendeduros Para mas información sobre nuestro fondo visita: https://emprendedurosventures.com/

The White House has struck a deal with two more drugmakers: Eli Lilly and Novo Nordisk. Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz discusses the administration's plan to make GLP-1s more affordable for Americans. Tesla shareholders voted to approve Elon Musk's $1 trillion pay package, as long as he reaches their lofty goals for the company. Musk biographer Walter Isaacson discusses the plan of milestones and Musk's history of exceeding investor expectations. Plus, U.S. airlines are beginning to cancel flights to manage shutdown-strained staffing of air traffic controllers, and Warren Buffett issued a warning on AI.  Dr. Mehmet Oz - 21:43Walter Isaacson - 38:56 In this episode:Dr. Mehmet Oz, @DrOzJoe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkinKatie Kramer, @Kramer_Katie Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

//The Wire//2300Z November 6, 2025////ROUTINE////BLUF: RIOTS ERUPT IN BIRMINGHAM AS SPORTS MATCH TRANSITIONS FROM GENERAL HOOLIGANISM INTO LARGER GEOPOLITICAL CONFLICT. OVAL OFFICE PRESS CONFERENCE HALTED DUE TO PHARMA EXEC COLLAPSING SUDDENLY.// -----BEGIN TEARLINE------International Events-United Kingdom: A state of civil unrest has emerged following a soccer match inflaming local tensions. Following a much-anticipated soccer match between a team from Tel Aviv and the local Aston Villa team in Birmingham, riots broke out overnight as rival gangs took their disputes to the street. Riot police were deployed to the stop the roving bands of "youths" from destroying property and generally causing disarray. Throughout the day today, the unrest has continued as long-held social tensions in Birmingham reached the boiling point. Over 700x police officers have been called up for duty tonight as the riots are planned to become much more significant with tonight's match against Tel Aviv.-HomeFront-Washington D.C. - This afternoon the White House announced a special press conference on the topic of pharmaceuticals. Most notably the press conference was called to announce a partnership with Novo Nordisk to lower the price of the Ozempic drug when purchased through the TrumpRX program.Analyst Comment: The press conference was abruptly cut short after Gordon Findlay, one of the senior executives of Novo Nordisk (the maker of Ozempic) collapsed in the Oval Office during the live broadcast. Dr. Oz, who was a part of the conference tried to render aid to him, and the rest of the press conference was delayed while Findlay received medical treatment. It's not certain why he dropped, but the White House stated that he was okay but feeling a bit lightheaded after the incident.-----END TEARLINE-----Analyst Comments: Once more, the misfortune of our friends across the pond gives Americans absolutely critical insight as to how things might go if a similar series of events were to pop off here in a major American city. For obvious reasons, a relatively nondescript soccer match is less about the sport and more about social and political issues, thus the unrest concerns. In short, it's a fairly kinetic and complex situation that serves in many ways as an indicator of the future to come.Birmingham has become a huge focal point for migrant housing, and these riots were not the work of the indigenous English. However, as with all soccer hooliganism, the rioting is almost never just one-sided. In this case, some (not all) Maccabi Tel Aviv fans were banned by British authorities from the Aston Villa stadium after starting a riot themselves, according to police. This resulted in two things happening simultaneously: the Islamic population of Birmingham rejoiced at this perceived geopolitical victory (and celebrated by breaking things and causing a ruckus), while many other Maccabi Tel Aviv fans lashed out in anger (again, also by breaking things and causing a ruckus). However, during the general state of unrest, rival gangs of mostly black and Islamic migrants (which had no interest in soccer) started fighting amongst themselves, adding in more diversity to the evening fray. Others still showed up to protest for more political purposes, but remained relatively calm throughout the evening. When the police arrived to restore order as this was getting underway last night (the day before the match), the more active elements of the crowds turned on them, targeting them with fireworks (which were probably used due to yesterday being Guy Fawkes Night). It is this unrest that continued from last night, throughout the day today, to tonight as well (the night of the match). So this is a two-day affair, not just a one-and-done scuffle, but a more prolonged period of unrest.In short, what's going on in Birmingham right now is more or less a state of mild pandem

Eric Criscuolo, Market Strategist at the NYSE, recaps a week where markets pulled back as Tech lost steam and defensive sectors gained ground. The Fed cut rates as expected, but Chair Powell's hawkish tone cooled hopes for further easing. Political headlines added uncertainty, with Democrats outperforming on Election Day and the Supreme Court questioning Trump-era tariffs. M&A activity surged, led by Kimberly Clark's $50B bid for Kenvue and a pharma bidding war between Pfizer and Novo Nordisk. Investors now look ahead to key earnings, economic data, and the impact of the government shutdown as the year-end trading calendar tightens.

Mehr Infos zum Kreditangebot von unserem Partner Scalable Capital findet ihr hier: https://de.scalable.capital/credit. Zalando und DHL liefern, Börse jubelt. Datadog überzeugt. Eli Lilly und Novo Nordisk haben Deal mit Trump. Duolingo will wachsen und nicht profitabel werden, Börse schimpft. Marvell wurde fast gekauft, HelloFresh hat Short-Attacke und Take-Two verschiebt GTA VI wieder. Lemonade (WKN: A2P7Z1) will das OpenAI der Versicherungswelt werden. Klappt das? Quantencomputing-Aktien waren an der Börse in den letzten Monaten Highflyer. Wie funktioniert die Technologie, wie funktioniert der Markt und wie erkennt man vertrauensvolle Firmen? Daniel Volz von Kipu Quantum klärt auf. Diesen Podcast vom 07.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Ny prisaftale om vægttabsmedicin med Novo Nordisk og Eli Lilly. Den fortsatte budkrig mellem Novo og Pfizer. Bavarian Nordics fremtid på børsen er sikret for nu. Danske regnskaber. DFDS skærer til. Gigantisk lønpakke til Elon Musk. Vært: Trine Duvander (trine.duvander@borsen.dk)

En Capital Intereconomía hemos seguido en directo la apertura del Ibex 35 y del resto de bolsas europeas, que arrancan la jornada con volatilidad y caídas moderadas arrastradas por el nuevo golpe al sector tecnológico y las dudas sobre el empleo en Estados Unidos. En el análisis de los mercados, Xavier Brun, responsable de renta variable europea en Trea AM, explicó que el tono negativo de las bolsas viene marcado por la corrección de las compañías de inteligencia artificial y el informe de la consultora privada ADP, que apunta a un recorte de empleo en octubre, lo que incrementa la incertidumbre sobre la fortaleza económica norteamericana. Brun también señaló que la batalla tecnológica entre EE.UU. y China sigue afectando al sentimiento inversor: las exportaciones chinas vuelven a caer, lastradas por la menor demanda estadounidense, y el bloqueo de chips de IA agrava la tensión entre ambos países. Al mismo tiempo, los mercados descuentan una bajada de tipos por parte de la Fed tras los últimos datos secundarios de empleo, aunque el presidente de la Fed de Chicago, Austan Goolsbee, ha advertido sobre el “oscurantismo de la inflación” y la necesidad de mantener la prudencia monetaria. En el plano empresarial, el sector farmacéutico fue protagonista después de que Eli Lilly y Novo Nordisk alcanzaran un acuerdo con la Administración Trump para reducir los precios de sus fármacos contra la obesidad, un movimiento que busca aliviar la presión política sobre el coste de los medicamentos y estabilizar el mercado sanitario. La jornada concluye con el consultorio de bolsa junto a Javier Alfayate, gestor de fondos, que respondió a las dudas de los oyentes sobre oportunidades en renta variable en un contexto de alta rotación sectorial y creciente nerviosismo en los mercados.

Millions of Americans will soon have direct access to popular weight-loss drugs at far lower prices than they pay now. That’s due to a deal announced between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk. William Brangham discussed the deal and its potential impact with Stacie Dusetzina of Vanderbilt University. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Gear up, freedom fighters—@intheMatrixxx and @shadygrooove charge into Season 7, Episode 212, "Trump Makes Announcement; Erika Kirk 1st Interview," dismantling deep-state distractions while spotlighting President Trump's powerhouse move to slash obesity drug prices to $149 a month for many Americans through deals with Eli Lilly and Novo Nordisk. As relentless exposers of globalist schemes, the hosts dissect this win for everyday patriots against Big Pharma greed, then pivot to Erika Kirk's raw, faith-fueled first TV sit-down since her husband Charlie Kirk's tragic assassination, where she honors his Turning Point USA legacy and stands firm amid loss. With sharp live breakdowns and unyielding America-First analysis, they equip you to reject establishment spin and defend sovereignty. The truth is learned, never told—the constitution is your weapon. Tune in at noon-0-five Eastern LIVE to stand with Trump! Trump, drug prices, Erika Kirk, Charlie Kirk, America First, MG Show, @intheMatrixxx, @shadygrooove, Turning Point USA, Big Pharma, patriotic intel mgshow_s7e212_trump_makes_announcement_erika_kirk_1st_interview Tune in weekdays at 12pm ET / 9am PST, hosted by @InTheMatrixxx and @Shadygrooove. Catch up on-demand on https://rumble.com/mgshow or via your favorite podcast platform. Where to Watch & Listen Live on https://rumble.com/mgshow https://mgshow.link/redstate X: https://x.com/inthematrixxx Backup: https://kick.com/mgshow PODCASTS: Available on PodBean, Apple, Pandora, and Amazon Music. Search for "MG Show" to listen. Engage with Us Join the conversation on https://t.me/mgshowchannel and participate in live voice chats at https://t.me/MGShow. Social Follow us on X: @intheMatrixxx https://x.com/inthematrixxx @ShadyGrooove https://x.com/shadygrooove Follow us on YouTube: ShadyGrooove https://www.youtube.com/c/TruthForFreedom Support the show: Fundraiser: https://givesendgo.com/helpmgshow Donate: https://mg.show/support Merch: https://merch.mg.show MyPillow Special: Use code MGSHOW at https://mypillow.com/mgshow for savings! Wanna send crypto? Bitcoin: bc1qtl2mftxzv8cxnzenmpav6t72a95yudtkq9dsuf Ethereum: 0xA11f0d2A68193cC57FAF9787F6Db1d3c98cf0b4D ADA: addr1q9z3urhje7jp2g85m3d4avfegrxapdhp726qpcf7czekeuayrlwx4lrzcfxzvupnlqqjjfl0rw08z0fmgzdk7z4zzgnqujqzsf XLM: GAWJ55N3QFYPFA2IC6HBEQ3OTGJGDG6OMY6RHP4ZIDFJLQPEUS5RAMO7 LTC: ltc1qapwe55ljayyav8hgg2f9dx2y0dxy73u0tya0pu All Links Find everything on https://linktr.ee/mgshow Intermission Music Lemurian Shores (with Lucentia) (~432 Hz) by Spheriá | https://soundcloud.com/spheriamusic Music promoted by https://www.chosic.com/free-music/all/ Creative Commons CC BY-SA 3.0 https://creativecommons.org/licenses/by-sa/3.0/

A federal judge ruled Thursday that the Trump administration must fully fund SNAP benefits amid the government shutdown, giving officials until Friday to secure the money. Meanwhile, as the shutdown continues, 40 major U.S. airports—including Los Angeles International, John F. Kennedy International, and Chicago O'Hare—will face a 10 percent reduction in flights starting Friday.President Donald Trump, just one day after Supreme Court arguments on his sweeping global tariffs in a case he called “one of the most important cases in the history of our country,” is doubling down—emphasizing that his tariff threats against Beijing were a national security lifeline that forced Xi Jinping to the negotiating table. The president is also set to meet with the leaders of all five Central Asian countries Thursday night as the United States works to expand its influence in a region increasingly courted by China.Trump also announced new agreements to expand access to and reduce the cost of weight loss drugs. The deals with pharmaceutical companies Novo Nordisk and Eli Lilly will broaden coverage for Medicare and Medicaid recipients and lower the prices paid by the federal government.

Millions of Americans will soon have direct access to popular weight-loss drugs at far lower prices than they pay now. That’s due to a deal announced between President Trump and pharmaceutical giants Eli Lilly and Novo Nordisk. William Brangham discussed the deal and its potential impact with Stacie Dusetzina of Vanderbilt University. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Howie and Harlan are joined by cardiologist Ali Rahimi, the founder of ALYKA Health, which uses a personalized mobile app to help patients manage their heart health between doctor's visits. Harlan discusses new developments in GLP-1 obesity drugs, including untested microdose treatments; Howie reviews a landmark study investigating whether broad prostate cancer screening saves lives. Show notes: GLP-1 Drugs "Microdosing aims to extend the lifespan of the GLP-1 compounding market" NIH: Regulatory Framework for Compounded Preparations Health & Veritas Episode 140: Lee Schwamm: Smarter Healthcare Systems With AI "FDA takes on GLP-1 compounding boom with warnings about misleading marketing" "Should You Microdose GLP-1 Drugs?" "How microdosing GLP-1 drugs became a longevity 'craze'" "Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates" "Trump Negotiating Deal With Ozempic Maker to Sell Some Weight-Loss Drugs for $149""Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" "How Ozempic's Maker Lost Its Shine After Creating a Wonder Drug" Ali Rahimi ALYKA Health Harlan Krumholz and Ali Rahimi, "Financial Barriers to Health Care and Outcomes After Acute Myocardial Infarction" "Why High Blood Pressure Matters to Your Health" Building a Better Delivery System: A New Engineering/Health Care Partnership NIH: The 21st Century Cures Act New Evidence on Prostate Cancer Screening and Breast Cancer Treatment National Cancer Institute: Cancer Stat Facts: Prostate Cancer" U.S. Preventive Services Task Force: Prostate Cancer: Screening" "The pros and cons of PSA tests for prostate cancer for midlife and older men" "Share on European Study of Prostate Cancer Screening — 23-Year Follow-up" "Early Detection of Prostate Cancer — Time to Fish or Cut Bait" "Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer" "Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.  

President Trump strikes a groundbreaking deal with Eli Lilly and Novo Nordisk to slash prices on popular weight-loss drugs for Medicare, Medicaid, and out-of-pocket patients. Nov 6th 2025 --- Please Like, Comment and Follow 'The Ray Appleton Show' on all platforms: --- 'The Ray Appleton Show’ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- 'The Ray Appleton Show’ Weekdays 11 AM -2 PM Pacific on News/Talk 580 AM & 105.9 KMJ | Website | Facebook | Podcast | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

President Donald Trump announced a major initiative aimed at lowering the cost of popular weight loss drugs in the U.S. Pres. Trump unveiled deals with Eli Lilly and Novo Nordisk to reduce prices on Wegovy (Novo Nordisk), Zepbound (Eli Lilly) and potential inclusion of Ozempic, primarily a diabetes drug also used for weight loss. Please Like, Comment and Follow 'Broeske & Musson' on all platforms: --- The ‘Broeske & Musson Podcast’ is available on the KMJNOW app, Apple Podcasts, Spotify or wherever else you listen to podcasts. --- ‘Broeske & Musson' Weekdays 9-11 AM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Facebook | Podcast| X | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

This episode covers: Cardiology this Week: A concise summary of recent studies Lp(a) - What to expect in the very near future Myocardial infarction in older and frail adults Mythbusters: is beetroot good for your heart? Host: Rick Grobbee Guests: JP Carpenter, Vijay Kunadian, Erik Stroes Want to watch that episode? Go to: https://esc365.escardio.org/event/2177 Want to watch that extended interview on Lp(a), go to: https://esc365.escardio.org/event/2177?resource=interview   Disclaimer  ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails.    Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel, Vijay Kunadian and Erik Stroes have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Dommer afviser Pfizers forsøg på at stoppe Novo-bud. Novo Nordisk må igen skrue ned for forventningerne. Vestas har succes med landvind og aktierne brager op med 15 pct. Ørsted lander milliardunderskud igen. Pandora skuffer og aktien falder. USA's nedlukning rammer nu også lufthavne. Højesteret vurderer Trumps toldkrig. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

Ja, de outlook is verlaagd en ja, de koers is vanaf de top 70 procent gedaald. Toch is Stan Westerterp van Bond Capital Partners positief over de Deense farmaceut. "Er is nog steeds sprake van groei, zowel van de operationele winst als de winst per aandeel. Ook de omzet steeg met 12 procent." Stan heeft voor zijn klanten de positie in Novo Nordisk dan ook uitgebreid. De onderliggende markt is gigantisch en er is nog een enorm potentieel. Zo kijkt Robbert Manders van het Antaurus Europe Fund er ook naar. "Het is een bedrijf met een paar mooie patenten en het geen dure farmaceut meer. Er zijn nog veel landen die kunnen beginnen met het vergoeden van Ozempic." Dat geeft wel aan dat er voldoende potentieel is voor Novo Nordisk. Ook voor Pharming zijn er lovende woorden. Dat aandeel is in een jaar tijd met 90 procent gestegen, wat niet gek is na - wederom - een verhoging van de omzetdoelstelling. De dure medicijnen, waar patiënten langdurig gebruik van maken, vinden steeds meer hun weg naar de markt. Verder in deze aflevering aandacht voor onder andere Ahold Delhaize, Philips, Wolters Kluwer en Palantir. De luisteraarsvragen komen aan bod en de experts geven hun tips. Stan tipt een Deens en een Nederlands bedrijf, Robbert tipt deze keer een Zwitsers aandeel. Geniet van de podcast! Let op: alleen het eerste deel is vrij te beluisteren. Wil je de hele podcast (luisteraarsvragen en tips) horen, wordt dan Premium lid van BeursTalk. Dat kost slechts 9,95 per maand, 99 euro voor een heel jaar. Abonneren kan hier!See omnystudio.com/listener for privacy information.

Unser Partner Scalable Capital ist der einzige Broker, den deine Familie zum Traden braucht. Bei Scalable Capital gibt's nämlich auch Kinderdepots. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Novo Nordisk enttäuscht schon wieder, Siemens Healthineers auch. McDonald's, BMW und Vestas überraschen dafür positiv. Apple zahlt die nächste Mrd. an Google. Milliardär Carl Icahn kauft sich in US-Werkstattkette Monro ein und Snap kooperiert mit Perplexity. Alle Probleme können KI, Cloud und Co. nicht lösen. Den Abfluss von Wasser zum Beispiel. Dafür braucht es Rohre und Drainagen, und die hat Advanced Drainage Systems (WKN: A117FL). MetaMask ist einer der bekanntesten Krypto-Wallet-Anbieter. Jetzt plant die Muttergesellschaft Consensys offenbar einen Börsengang zu einer Milliardenbewertung. Außerdem geht's um den Krypto-Crash der letzten Tage. Diesen Podcast vom 06.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

A.M. Edition for Nov. 5. Democrats notched major victories last night, prompting President Trump's ire on social media. WSJ editor Aaron Zitner breaks down what the results mean for both parties and how they could shape the national political landscape going into the 2026 midterms. Plus, Republican senators meet at the White House this morning as the government shutdown becomes the longest in history. And we look at the competition facing weight-loss giant Novo Nordisk. Caitlin McCabe hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus, Republican senators meet at the White House this morning as the government shutdown becomes the longest in history. And we look at the competition facing weight-loss giant Novo Nordisk. Caitlin McCabe hosts.  Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sara Eisen, Carl Quintanilla, and David Faber kicked off the hour with a slew of fresh data on the economic front - and more on what investors need to know as the Supreme Court kicks off Day 1 of arguments around the legality of President Trump's global tariffs... Plus: Bank of America CEO Brian Moynihan joined the team with his read on the economy, live from the company's first investor day in more than 15 years - while the CEO of Lemonade gave his take on how AI is changing the insurance business as those shares surge post-results.  Also in focus: the growing bidding war between Novo Nordisk and Pfizer that could impact the future of the weightloss market... and a deep-dive on what's driving Pinterest shares to their worst day on record. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On today's episode of The Gist Healthcare Podcast, CMS finalizes a Medicare pay bump for physicians. Kimberly-Clark to purchase Tylenol maker Kenvue, and Pfizer sues to block Novo Nordisk's merger with an obesity startup. Hosted on Acast. See acast.com/privacy for more information.

New York's mayor-elect, Zohran Mamdani, is promising to tackle the city's soaring cost of living. Ed Butler looks at what his victory could mean for businesses.Also, Eli Lilly and Novo Nordisk agree to slash the cost of blockbuster weight-loss drugs like Ozempic and Wegovy under a new Medicare deal. And why Shein is facing a backlash in France.

Listen to Daily Global #News from Grecian Echoes WNTN 1550 AM -  Democrats won the races in the first major elections since Trump became president - Trump is negotiating a deal with Eli Lilly and Novo Nordisk that would lower obesity drug price - The government shutdown has entered its 36th day, setting a new record

Did you know your sleep habits could be affecting your weight? Join us with Dr. Michael Mak as he explains the powerful connection between sleep and obesity, why sleep is essential for overall health, and tips for getting a better night's rest.The medical information in this podcast is provided as an information resource only. It is not in any way intended to be nor should you rely on it as a substitute for professional medical evaluation, diagnosis, advice and treatment.This episode was sponsored by Novo Nordisk. It was created independently by My Weight - What to Know with no influence from Novo Nordisk.

Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic. It underscores the challenges facing its new chief executive Mike Doustdar. He spoke to Bloomberg's Guy Johnson about the experience so far. See omnystudio.com/listener for privacy information.

From Wall Street to Main Street, the latest on the markets and what it means for your money. Updated regularly on weekdays, featuring CNBC expert analysis and sound from top business newsmakers. Anchored by CNBC's Jessica Ettinger. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Stock market update for November 5, 2025.Follow us on Instagram ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@therundowndaily⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠This video is for informational purposes only and reflects the views of the host and guest, not Public Holdings or its subsidiaries. Mentions of assets are not recommendations. Investing involves risk, including loss. Past performance does not guarantee future results. For full disclosures, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Public.com/disclosures⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump's drug-pricing plans, including TrumpRx. WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Further Reading: Novo Nordisk Sweetens Offer for Metsera - WSJ Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk The Day Pharma's Weight-Loss Gold Rush Intensified Pfizer Profit Falls Amid Lower Covid-19 Drug Demand Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera Novo Nordisk to Shake Up Board After Obesity-Market Challenges Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings AbbVie Lifts Profit Outlook as Sales Rise Bristol Myers Squibb Profit Soars, Raises Revenue Guidance Merck Profit Rises on Strong Keytruda Demand GSK Lifts Guidance After Specialty Medicines Boost Sales Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains Learn more about your ad choices. Visit megaphone.fm/adchoices

Palantir lifted its 2025 revenue guidance and Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera. Plus, OpenAI inked a $38bn computing deal with Amazon, and the FT's Claire Jones explains how the Trump administration is considering pushing for wider global dollar adoption. Mentioned in this podcast:Palantir lifts 2025 sales outlook after posting strong quarterly growthPfizer files second lawsuit to block Novo Nordisk's $9bn Metsera bidOpenAI strikes $38bn computing deal with AmazonUS pushes for wider global dollar adoptionToday's FT News Briefing was produced by Sonja Hutson, and Marc Filippino. Our show was mixed by Kelly Garry. Additional help from Michela Tindera, Michael Lello and David da Silva. The FT's acting co-head of audio is Topher Forhecz. The show's theme music is by Metaphor Music.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Plus: First Brands' new management accuses founder Patrick James of fraud. And Stellantis's Chrysler recalls over 300,000 hybrid Jeeps over battery fire risks. Zoe Kuhlkin hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

The tech sector under pressure: Carl Quintanilla, Jim Cramer and David Faber began the show with Palantir shares down sharply despite better-than-expected Q3 results and upbeat revenue guidance. Hear what CEO Alex Karp told CNBC about short sellers as Palantir shares remain among this year's best performers on the S&P 500. Pfizer and Novo Nordisk sweetened their respective offers to buy obesity drugmaker Metsera. Norway's sovereign wealth fund — the world's biggest — said it will vote against Tesla CEO Elon Musk's massive pay package that could total $1 trillion. Shopify President Harley Finkelstein joined the program to discuss the company's earnings and its outlook for the holiday quarter. Also in focus: Earnings winners and losers. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Pfizer files a second lawsuit against Metsera and Novo Nordisk. And OpenAI pays Amazon $38 billion for computing power in a multiyear deal. Zoe Kuhlkin hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Get the latest buzz on GLP-1 therapies and the future of metabolic medicine! This episode provides an in-depth look at what's coming out of Obesity Week in Atlanta, GA, featuring expert insights from Dave Knapp from On the Pen.Key Topics & Breakthroughs:Corporate Battle for Biotech: We break down the surprise counteroffer by Novo Nordisk to acquire Metsera, the obesity biotech company that Pfizer had recently announced it was buying, setting the stage for a major pharmaceutical turf war.Pipeline Watch: Dive into the plethora of new therapies in current clinical trials, including the latest developments from Viking Therapeutics and the push for Oral GLP-1s.GLP-1's New Frontier: Discover the groundbreaking research on GLP-1's potential role in treating alcohol and narcotics addictions. We also discuss Brenipatide and its surprising dual focus on alcohol abuse and asthma.Tune in for a comprehensive review of the medications, mergers, and clinical trials shaping the next generation of weight loss and metabolic treatments.______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy #ObesityCare #PatientAdvocate #GLP1Community #RealGLP1StoriesSend us Fan Mail! GetClaimable.com/PlusSideZ to appeal your GLP-1 Insurance Denails and use code PlusSideZ to save! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==